Stock listing
BOATS:SLDB Solid Biosciences Inc. Stock
US listing (BOATS) of Solid Biosciences Inc. · home listing NASDAQ:SLDB
Follow Solid Biosciences Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SLDB
$6.25 USD -0.10 (-1.6%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SLDB
- Day range
- $6.20 – $6.53 USDNov 20, 2026
- Volume
- 1.56M sharesNov 20, 2026
- Market cap
- $697.6M USDAt the close on Nov 20, 2026 · price × 111.6M shares outstanding
- 52-week range
- $4.45 – $11.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.44M USDMedian day 1.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SLDB · Home | $6.25 USD | -0.10 (-1.6%) | 1,558,939 | $6.34 | $6.53 | $6.195 | $6.35 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLDB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.25 | -0.10 | -1.6% | $6.34 | $6.53 | $6.195 | 1,558,939 | |
| $6.35 | +0.12 | +1.9% | $6.22 | $6.425 | $6.08 | 1,206,527 | |
| $6.23 | -0.25 | -3.9% | $6.48 | $6.57 | $6.10 | 1,133,949 | |
| $6.48 | -0.36 | -5.3% | $6.76 | $6.94 | $6.45 | 872,638 | |
| $6.84 | -0.16 | -2.3% | $7.00 | $7.05 | $6.565 | 975,452 | |
| $7.00 | -0.60 | -7.9% | $7.59 | $7.59 | $6.97 | 1,322,914 | |
| $7.60 | +0.43 | +6.0% | $7.26 | $7.855 | $7.179 | 1,957,911 | |
| $7.17 | +0.15 | +2.1% | $6.88 | $7.32 | $6.845 | 1,721,858 | |
| $7.02 | +0.43 | +6.5% | $6.87 | $7.245 | $6.585 | 2,373,416 | |
| $6.59 | +0.41 | +6.6% | $6.18 | $6.73 | $6.18 | 1,426,523 | |
| $6.18 | -0.34 | -5.2% | $6.60 | $6.62 | $6.01 | 1,435,885 | |
| $6.52 | +0.24 | +3.8% | $6.59 | $6.68 | $6.228 | 1,058,635 | |
| $6.28 | +0.28 | +4.7% | $6.09 | $6.32 | $6.061 | 770,148 | |
| $6.00 | -0.20 | -3.2% | $6.28 | $6.305 | $5.83 | 1,129,328 | |
| $6.20 | -0.19 | -3.0% | $6.30 | $6.43 | $6.02 | 873,117 | |
| $6.39 | -0.09 | -1.4% | $6.51 | $6.65 | $6.27 | 964,669 | |
| $6.48 | +0.29 | +4.7% | $6.08 | $6.525 | $5.96 | 1,510,803 | |
| $6.19 | +0.38 | +6.5% | $5.84 | $6.23 | $5.765 | 1,551,480 | |
| $5.81 | -0.11 | -1.9% | $6.00 | $6.09 | $5.74 | 1,070,933 | |
| $5.92 | -0.27 | -4.4% | $6.12 | $6.23 | $5.78 | 769,967 | |
| $6.19 | -0.22 | -3.4% | $6.33 | $6.52 | $6.095 | 1,217,098 | |
| $6.41 | +0.01 | +0.2% | $6.46 | $6.58 | $6.32 | 1,147,634 | |
| $6.40 | +0.48 | +8.1% | $5.93 | $6.52 | $5.86 | 1,465,155 | |
| $5.92 | +0.39 | +7.1% | $5.62 | $6.04 | $5.56 | 1,847,907 | |
| $5.53 | -0.21 | -3.7% | $5.73 | $5.825 | $5.48 | 1,401,831 | |
| $5.74 | +0.275 | +5.0% | $5.55 | $5.835 | $5.385 | 2,033,374 | |
| $5.465 | -0.355 | -6.1% | $5.66 | $5.71 | $5.40 | 2,378,470 | |
| $5.82 | -0.89 | -13.3% | $6.65 | $6.65 | $5.70 | 2,869,736 | |
| $6.71 | -0.16 | -2.3% | $6.85 | $6.93 | $6.69 | 601,311 | |
| $6.87 | +0.05 | +0.7% | $6.81 | $7.045 | $6.755 | 726,812 | |
| $6.82 | -0.03 | -0.4% | $6.75 | $6.88 | $6.635 | 1,308,109 | |
| $6.85 | -0.07 | -1.0% | $6.76 | $6.975 | $6.69 | 744,708 | |
| $6.92 | -0.14 | -2.0% | $7.11 | $7.11 | $6.65 | 1,188,692 | |
| $7.06 | +0.21 | +3.1% | $6.88 | $7.205 | $6.77 | 1,372,173 | |
| $6.85 | -0.13 | -1.9% | $7.14 | $7.26 | $6.78 | 1,198,189 | |
| $6.98 | -0.25 | -3.5% | $7.14 | $7.245 | $6.91 | 1,582,201 | |
| $7.23 | +0.07 | +1.0% | $7.24 | $7.54 | $7.16 | 1,711,185 | |
| $7.16 | -0.12 | -1.6% | $7.26 | $7.325 | $6.90 | 1,392,322 | |
| $7.28 | -0.01 | -0.1% | $7.14 | $7.345 | $7.095 | 1,413,513 | |
| $7.29 | -0.19 | -2.5% | $7.53 | $7.54 | $7.15 | 1,420,530 | |
| $7.48 | -0.54 | -6.7% | $7.95 | $8.00 | $7.35 | 1,349,278 | |
| $8.02 | -0.90 | -10.1% | $8.89 | $8.91 | $8.001 | 1,088,231 | |
| $8.92 | +0.38 | +4.4% | $8.67 | $8.955 | $8.56 | 1,305,487 | |
| $8.54 | -0.37 | -4.2% | $9.03 | $9.03 | $8.525 | 1,170,809 | |
| $8.91 | +0.04 | +0.5% | $8.87 | $8.97 | $8.635 | 4,090,597 | |
| $8.87 | +0.15 | +1.7% | $8.94 | $8.97 | $8.60 | 1,193,532 | |
| $8.72 | +0.35 | +4.2% | $8.62 | $8.755 | $8.265 | 2,256,406 | |
| $8.37 | -0.37 | -4.2% | $8.69 | $8.69 | $8.16 | 1,514,418 | |
| $8.74 | +0.04 | +0.5% | $8.82 | $9.109 | $8.71 | 1,025,185 | |
| $8.70 | -0.37 | -4.1% | $9.205 | $9.365 | $8.655 | 1,113,857 | |
| $9.07 | -0.47 | -4.9% | $9.36 | $9.36 | $9.01 | 855,917 | |
| $9.54 | -0.39 | -3.9% | $9.77 | $9.95 | $9.53 | 646,346 | |
| $9.93 | -0.32 | -3.1% | $10.00 | $10.09 | $9.58 | 742,815 | |
| $10.25 | -0.17 | -1.6% | $10.20 | $10.48 | $10.20 | 495,327 | |
| $10.42 | +0.135 | +1.3% | $10.30 | $10.46 | $10.05 | 728,483 | |
| $10.29 | +0.405 | +4.1% | $9.92 | $10.44 | $9.75 | 894,270 | |
| $9.88 | +0.30 | +3.1% | $9.44 | $9.95 | $9.37 | 803,305 | |
| $9.58 | -0.19 | -1.9% | $9.73 | $9.73 | $9.37 | 686,620 | |
| $9.77 | -0.36 | -3.6% | $10.02 | $10.10 | $9.72 | 621,524 | |
| $10.13 | +0.41 | +4.2% | $10.03 | $10.27 | $9.89 | 988,931 | |
| $9.72 | -0.17 | -1.7% | $9.84 | $9.85 | $9.60 | 594,174 | |
| $9.89 | +0.73 | +8.0% | $9.33 | $9.90 | $9.33 | 1,260,522 | |
| $9.16 | -0.14 | -1.5% | $9.28 | $9.28 | $8.86 | 1,114,777 | |
| $9.30 | +0.20 | +2.2% | $9.34 | $9.665 | $9.23 | 790,365 | |
| $9.10 | -0.64 | -6.6% | $9.51 | $9.57 | $8.81 | 1,076,892 |
Splits
1 split · NASDAQ:SLDB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation |
- Ticker
- BOATS:SLDB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 18 slides
Latest news
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Nov 10, 2026
Closed $7.17 (+2.1%) on Nov 10, 2026
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026
Closed $6.18 (-5.2%) on Nov 5, 2026
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 4, 2026
Closed $6.18 (-5.2%) on Nov 5, 2026
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
Oct 26, 2026
Closed $5.81 (-1.9%) on Oct 26, 2026
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Oct 20, 2026
Closed $6.40 (+8.1%) on Oct 20, 2026
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2026
Closed $6.85 (-1.9%) on Oct 2, 2026
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
Jun 2, 2026
Closed $6.58 (-8.5%) on Jun 2, 2026
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Closed $7.38 (-4.4%) on May 13, 2026
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
May 7, 2026
Closed $7.07 (-1.8%) on May 7, 2026
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
Apr 30, 2026
Closed $7.26 (+3.0%) on Apr 30, 2026
Solid Biosciences Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 108 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 1 call with a replay · 1 with a transcript · latest Apr 27, 2022
- Decks
- 14 decks · latest September 2026
Where Solid Biosciences Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SLDB · Home listing | NASDAQ | United States | USD |
| BOATS:SLDB · This page | BOATS | United States | USD |
Valuation
Price/book 2.0× against a median of 4.1×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $368.3M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.85
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc. · NASDAQ:SLDB | US$697.6M | US$368.3M | n/a | n/a | n/a | 2.0× | n/a | 0.1× | 1.85 |
| Monte Rosa Therapeutics, Inc. · NASDAQ:GLUE | US$738.3M | US$196.8M | n/a | 2.8× | n/a | 1.5× | −186.2% | 0.1× | 0.92 |
| Aimed Bio Inc. · KRX:0009K0 | US$726.5M | US$657.3M | 25.2× | 13.2× | 34.0× | 4.8× | 57.8% | 0.0× | n/a |
| Aura Biosciences, Inc. · NASDAQ:AURA | US$715.0M | US$433.9M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.07 |
| Attovia Therapeutics, Inc. · NASDAQ:ATTO | US$689.3M | US$297.2M | n/a | 220× | n/a | 1.7× | n/a | 0.0× | n/a |
| Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX | US$681.2M | US$549.9M | n/a | 14.3× | n/a | 4.2× | −161.8% | 0.3× | 1.15 |
| CARsgen Therapeutics Holdings Ltd. · HKEX:2171 | US$676.0M | US$477.2M | n/a | 25.4× | n/a | 4.1× | −77.9% | 0.1× | n/a |
| Philogen SpA · MIL:PHIL | US$672.3M | US$532.7M | 2.7× | 1.5× | n/a | 1.6× | 71.8% | 0.0× | n/a |
| Nuvectis Pharma, Inc. · NASDAQ:NVCT | US$666.8M | US$526.1M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | 0.84 |
| Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC | US$665.9M | US$519.0M | 3.8× | 2.5× | 2.9× | 4.3× | 84.7% | 0.0× | n/a |
| Oscotec Inc. · KRX:039200 | US$664.8M | US$664.8M | 11.6× | 6.3× | n/a | 4.5× | 54.0% | 0.0× | n/a |
| Median of the others | US$678.6M | US$522.6M | 7.7× | 9.7× | 18.5× | 4.1× | 54.0% | 0.0× | 1.00 |
Forecasts
10 strong buy · 5 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.71 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.67 · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Bo Cumbo | President and CEO |
| Lynne Sullivan | Chief Financial Officer at Unity Biotechnology |
| Sukumar Nagendran | President, Head of Research & Development, Taysha Gene Therapies |
Board
| Director | Role |
|---|---|
| Ian F. Smith | Chairman of the Board |
| Clare Kahn | Board Member |
| Georgia Keresty | Board Member |
| Martin Freed | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Solid Biosciences (NASDAQ:SLDB) Q1 2022 Earnings Call | Wed, Apr 27, 2022 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −5.2% |
| Q2 2026 | Aug 6, 2026 · After close | −3.7% |
| Q1 2026 | May 13, 2026 | −1.2% |
| Q4 2025 | Mar 19, 2026 · After close | −1.3% |
| Q3 2025 | Nov 3, 2025 · After close | −15.3% |
| Q2 2025 | Aug 12, 2025 · After close | +10.6% |
| Q1 2025 | May 15, 2025 · After close | +7.0% |
| Q4 2024 | Mar 11, 2025 · Before open | +10.2% |
| Q3 2024 | Nov 6, 2024 · After close | −6.0% |
| Q2 2024 | Aug 13, 2024 · After close | +14.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −2.7% |
| Q4 2023 | Mar 13, 2024 · Before open | +7.3% |
| Q3 2023 | Nov 8, 2023 · After close | −23.7% |
| Q2 2023 | Aug 14, 2023 · After close | −2.5% |
| Q1 2023 | May 11, 2023 · Before open | +3.9% |
| Q4 2022 | Mar 23, 2023 · Before open | −0.3% |
| Q3 2022 | Nov 10, 2022 · Before open | +2.2% |
| Q2 2022 | Aug 11, 2022 · Before open | +3.6% |
| Q1 2022 | Apr 27, 2022 · Before open | −17.0% |
| Q4 2021 | Mar 14, 2022 · Before open | −6.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 18 slides | September 2026 |
| Technical Presentation (April 2026) | Technical | 16 slides | April 2026 |
| Cardiovascular Clinical Trialist (CVCT) Forum 2025 | Conference | 25 slides | December 2025 |
| Technical Presentation (December 2025) | Technical | 11 slides | December 2025 |
| Investor Presentation (November 2025) | Investor deck | 45 slides | Nov 3, 2025 |
| ASGCT 2025 | Conference | 19 slides | May 2025 |
| ASGCT 2025 | Conference | 14 slides | May 2025 |
| Technical Presentation (February 2025) | Technical | 23 slides | Feb 18, 2025 |
| 42nd Annual J.P. Morgan Healthcare Conference 2024 | Conference | 30 slides | Jan 8, 2024 |
| 41st Annual J.P. Morgan Healthcare Conference (January 2023) | Conference | 27 slides | Jan 9, 2023 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (September 2022) | Merger or acquisition | 31 slides | Sep 30, 2022 |
| PPMD 2019 Annual Conference | Conference | 23 slides | Jun 28, 2019 |
| Parent Project Onlus Annual Conference 2019 | Conference | 17 slides | Feb 16, 2019 |
| Investor Presentation (January 2019) | Investor deck | 29 slides | Jan 8, 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$200M · US$4.03 a share · Jefferies +3 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), William Blair (co-lead), H.C. Wainwright & Co. Buyers: Adage Capital Partners LP; Bain Capital Life Sciences; Invus; Perceptive Advisors; RA Capital Management; TCGX; Venrock Healthcare Capital Partners; Vestal Point Capital | Feb 18, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 8.09M | 13.6M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.64M | 2.46M | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.0K | 56.0K |
| Gross profit | -1.64M | -2.46M | -2.58M | 8.09M | 13.6M | -3.92M | -2.82M | -1.57M | -448.0K | -56.0K |
| Research and development | 140.3M | 96.4M | 76.6M | 78.4M | 58.7M | 64.9M | 94.7M | 58.0M | 39.9M | 20.1M |
| Selling, general and administrative | 38.9M | 33.3M | 27.8M | 28.9M | 27.1M | 21.6M | 24.6M | 17.7M | 15.0M | 5.46M |
| Operating income | -179.2M | -129.7M | -104.3M | -106.5M | -72.3M | -88.4M | -119.3M | -75.7M | -54.9M | -25.6M |
| Depreciation and amortization | 1.64M | 2.46M | 2.58M | 2.41M | 2.96M | 3.92M | 2.82M | 1.57M | 448.0K | 56.0K |
| EBITDA | -177.6M | -127.3M | -101.7M | -104.0M | -69.3M | -84.5M | -116.5M | -74.1M | -54.4M | -25.5M |
| Interest expense | -203.0K | 340.0K | 440.0K | 20.5M | 66.0K | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -174.2M | -124.6M | -96.0M | -86.0M | -72.2M | -88.3M | -117.2M | -74.8M | -53.2M | -23.8M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.28M | -2.60M |
| Net income | -174.3M | -124.7M | -96.0M | -86.0M | -72.2M | -88.3M | -117.2M | -74.8M | -52.1M | -21.5M |
| Earnings per share, basic | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | -2.91 | -2.25 | -2.88 | -10.14 |
| Earnings per share, diluted | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | -2.91 | -2.25 | -2.88 | -10.14 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 59.9M | 80.2M | 74.0M | 155.4M | 119.1M | 154.7M | 76.0M | 86.4M | 52.1M | 7.68M |
| Short-term investments | 128.0M | 68.7M | 49.6M | 58.3M | 88.6M | 0 | 7.48M | 36.1M | 17.0M | 30.0M |
| Receivables | 0 | 110.0K | 0 | |||||||
| Inventory | 6.01M | |||||||||
| Current assets | 205.5M | 157.3M | 129.7M | 219.6M | 222.6M | 158.9M | 86.3M | 128.6M | 70.7M | 40.0M |
| Property, plant and equipment | 4.17M | 4.75M | 6.62M | 9.66M | 6.46M | 8.15M | 11.6M | 10.4M | 2.43M | 452.0K |
| Total assets | 232.5M | 188.7M | 164.9M | 260.3M | 232.4M | 171.2M | 103.5M | 139.6M | 76.2M | 40.6M |
| Accounts payable | 3.22M | 4.24M | 2.03M | 3.24M | 4.46M | 3.27M | 7.12M | 3.69M | 5.07M | 2.98M |
| Current liabilities | 33.5M | 30.3M | 14.5M | 22.5M | 23.6M | 24.5M | 18.3M | 12.5M | 11.3M | 6.87M |
| Total debt | 21.2M | 24.2M | 26.3M | 28.5M | 2.06M | 5.15M | 7.07M | 1.89M | ||
| Total liabilities | 52.5M | 51.4M | 38.5M | 48.6M | 24.2M | 39.1M | 23.4M | 14.4M | 11.3M | 78.5M |
| Shareholders' equity | 180.0M | 137.2M | 126.5M | 211.7M | 208.2M | 132.1M | 80.0M | 125.2M | -59.3M | -37.9M |
| Shares outstanding | 79.0M | 40.5M | 20.4M | 19.6M | 7.36M | 84.9M | 46.0M | 35.4M | 0 | 46.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -156.3M | -100.0M | -94.2M | -98.0M | -77.8M | -56.6M | -92.7M | -70.2M | -43.2M | -20.1M |
| Capital spending | -1.15M | -654.0K | -1.51M | -3.02M | -1.28M | -899.0K | -4.39M | -7.78M | -2.28M | -392.0K |
| Free cash flow | -157.4M | -100.7M | -95.7M | -101.0M | -79.0M | -57.5M | -97.1M | -78.0M | -45.5M | -20.5M |
| Cash from investing | -58.5M | -16.1M | 9.69M | 59.2M | -91.1M | 6.60M | 24.5M | -26.8M | 10.4M | -4.05M |
| Cash from financing | 194.4M | 122.4M | 3.12M | 74.8M | 135.0M | 128.7M | 57.9M | 131.5M | 77.1M | 3.42M |
| Share buybacks | -1.68M | -5.11M | 0 | 72.6M | 134.9M | 19.3M | 57.9M | 131.5M | 79.5M | 3.42M |
| Change in cash | -20.3M | 6.34M | -81.4M | 36.0M | -33.9M | 78.7M | -10.3M | 34.5M | 44.3M | -20.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3ASR · Registration statement | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 424B7 · Prospectus | Jun 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 19, 2026 | Offer document | SEC |
| S-3 · Registration statement | Mar 19, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 6, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 3, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 13, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 28, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| 8-K · Current report | May 15, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 15, 2025 | Offer document | SEC |
| S-3 · Registration statement | May 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 12, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 11, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Mar 6, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 21, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 19, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 18, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 18, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2025 | Current report | SEC |
| 8-K · Current report | Feb 18, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
This page holds 200 of 739 filings. Open Filings
Cap table
Built by 6ix from Solid Biosciences Inc.’s releases · as of Oct 30, 2026
- Common shares
- 111,610,531
- Fully diluted
- 111,610,531
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 111,610,531 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 111,610,531 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Jan 25, 2018 – Jan 11, 2024 · Past |
| Alexander Cumbo Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Vor Biopharma Inc. (Chair of the Compensation Committee · Since at least Jul 16, 2025); Climb Bio, Inc. (Director · Since at least Mar 28, 2025); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past) | President and CEO, Director · Since at least Dec 2, 2022 |
| Stephen J DiPalma Other companies: Inozyme Pharma Inc (Interim CFO · May 17, 2021 – May 17, 2021 · Past); Generation Bio Co (See Remarks · Jun 11, 2020 – Jun 11, 2020 · Past); Chemomab Therapeutics Ltd. (Chief Financial Officer · May 1, 2020 – May 1, 2020 · Past); Spero Therapeutics, Inc. (See Remarks · Nov 8, 2019 – Jul 15, 2023 · Past); Interleukin Genetics Inc (Interim CFO · Jul 29, 2016 – Jul 29, 2016 · Past) | Interim CFO · Jan 29, 2021 – Jan 29, 2021 · Past |
| Lynne Sullivan Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Unity Biotechnology Inc (CFO & Head of Corp. Dev. · Aug 1, 2020 – Apr 2, 2025 · Past); BiomX Inc. (Director · Nov 4, 2019 – Mar 1, 2023 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past) | Chief Financial Officer at Unity Biotechnology · Since at least Jan 25, 2018 |
| Robert L. Huffines Other companies: Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); Becton, Dickinson and Company (Director · Since at least Dec 1, 2025); Insulet Corporation (Director · Since at least Oct 23, 2025); Walgreens Boots Alliance Inc (Director · Since at least Jan 25, 2024) | Director · Jun 7, 2022 – Dec 13, 2022 · Past |
| Ian Smith Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Stoke Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Sep 19, 2023); Foghorn Therapeutics Inc. (Director · Since at least Apr 27, 2021) | Chairman of the Board · Since at least Dec 10, 2020 |
| Sukumar Nagendran Other companies: Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); AveXis Inc (Sr. VP & Chief Medical Officer · Feb 10, 2016 – May 15, 2018 · Past) | President, Head of Research & Development, Taysha Gene Therapies · Since at least Sep 12, 2018 |
| Bo Cumbo Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Climb Bio, Inc. (Board Member · Since at least May 14, 2025) | President and CEO · Since at least Jun 2, 2026 |
| Clare Kahn Other companies: Stoke Therapeutics, Inc. (Director · Since at least Apr 7, 2026) | Board Member · Since at least Nov 5, 2026 |
| Erin Powers Brennan Other companies: Covetrus Inc (See Remarks · Feb 7, 2019 – Jul 1, 2020 · Past) | Chief Legal Officer, Secretary · Mar 1, 2021 – May 2, 2022 · Past |
All 21 people
| Person | Seat |
|---|---|
| Jennifer Lynn Ziolkowski Other companies: Vigil Neuroscience Inc (Chief Financial Officer, Director · Since at least Jan 6, 2022) | CFO, Treasurer & Asst. Secy · Jan 25, 2018 – Jan 27, 2021 · Past |
| Kevin Tan Other companies: Cartesian Therapeutics, Inc. (Chief Financial Officer · Sep 20, 2021 – Jan 3, 2022 · Past) | CFO & Treasurer · Since at least Jan 9, 2023 |
| Martin Freed Other companies: Dicerna Pharmaceuticals Inc (Director · Jun 14, 2016 – Dec 28, 2021 · Past) | Board Member · Since at least Jun 22, 2018 |
| Carl Ashley Morris | Chief Scientific Officer · Jan 25, 2021 – Jan 27, 2023 · Past |
| David T Howton | Chief Operating Officer · Since at least Aug 14, 2025 |
| Gabriel Brooks | Chief Medical Officer · Since at least Oct 18, 2026 |
| Georgia Keresty | Board Member · Since at least Nov 5, 2026 |
| Ilan Ganot | Director · Since at least Jan 25, 2018 |
| Joel Solomon Zev Schneider | Chief Operating Officer · Jan 25, 2018 – Mar 14, 2022 · Past |
| Jorge Armando Quiroz | Chief Medical Officer · Jan 25, 2018 – Jan 23, 2019 · Past |
| Paul Herzich | Chief Technology Officer · Since at least Aug 14, 2025 |
Log in to ask 6ix AI your own questions about Solid Biosciences Inc.